Chemomab has gained a new EU patent for CM-101 covering its use in liver diseases including PSC, adding to the robust patent estate in major territories..
Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the Patent Offices in Brazil and Israel have granted new patents for CM-101, Chemomab's first-in-class monoclonal antibody that neutralizes CCL24, a novel disease target that has been shown to play a critical role in the processes that drive diseases involving fibrosis and inflammation. CM-101 i
Between an influx of transplants and natives eager to leave the state, there s been a lot of change in Texas. Here s why folks throughout the state have stayed.